Total Payments
$6,091
2024 Payments
$3,073
Companies
40
Transactions
212
Medicare Patients
1,317
Medicare Billing
$99,161
Payment Breakdown by Category
Food & Beverage$4,095 (67.2%)
Other$1,080 (17.7%)
Education$914.90 (15.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,095 | 191 | 67.2% |
| Long term medical supply or device loan | $1,080 | 11 | 17.7% |
| Education | $914.90 | 10 | 15.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,695 | 57 | $0 (2024) |
| Seagen Inc. | $546.20 | 8 | $0 (2023) |
| Astellas Pharma US Inc | $528.01 | 12 | $0 (2024) |
| GENZYME CORPORATION | $328.68 | 15 | $0 (2024) |
| PFIZER INC. | $230.20 | 12 | $0 (2024) |
| ABBVIE INC. | $212.98 | 9 | $0 (2024) |
| Daiichi Sankyo Inc. | $178.48 | 9 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $178.01 | 7 | $0 (2023) |
| Janssen Biotech, Inc. | $171.32 | 6 | $0 (2024) |
| Incyte Corporation | $170.17 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,073 | 90 | Novartis Pharmaceuticals Corporation ($1,391) |
| 2023 | $1,651 | 75 | Novartis Pharmaceuticals Corporation ($239.50) |
| 2022 | $1,272 | 41 | Seagen Inc. ($425.91) |
| 2021 | $94.93 | 6 | GENZYME CORPORATION ($38.51) |
All Payment Transactions
212 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Exelixis Inc. | — | Education | In-kind items and services | $89.99 | General |
| 12/10/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $22.81 | General |
| Category: Oncology | ||||||
| 11/27/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $29.88 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $25.38 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Oncology | ||||||
| 11/15/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $26.85 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $127.40 | General |
| Category: Hematology/Oncology | ||||||
| 11/07/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $6.59 | General |
| Category: Oncology | ||||||
| 11/01/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.72 | General |
| 10/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.99 | General |
| 10/25/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $3.67 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.62 | General |
| 10/09/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $20.99 | General |
| Category: Oncology | ||||||
| 10/08/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $1.40 | General |
| Category: Oncology | ||||||
| 10/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 99 | 115 | $27,343 | $8,079 |
| 2022 | 3 | 132 | 163 | $36,904 | $11,552 |
| 2021 | 5 | 370 | 564 | $115,643 | $40,055 |
| 2020 | 6 | 716 | 979 | $168,327 | $39,475 |
Total Patients
1,317
Total Services
1,821
Medicare Billing
$99,161
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 80 | 95 | $24,387 | $7,130 | 29.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 20 | $2,956 | $948.76 | 32.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 74 | 98 | $22,857 | $7,249 | 31.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 20 | $7,358 | $2,275 | 30.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 42 | 45 | $6,689 | $2,028 | 30.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 209 | 380 | $82,592 | $28,699 | 34.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 45 | 60 | $18,862 | $6,746 | 35.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 83 | 91 | $13,552 | $4,430 | 32.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 17 | 17 | $493.00 | $132.09 | 26.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 16 | 16 | $144.00 | $48.00 | 33.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 227 | 382 | $107,724 | $24,959 | 23.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 105 | 115 | $22,080 | $4,858 | 22.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 47 | 72 | $13,680 | $3,320 | 24.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 29 | 34 | $12,920 | $2,964 | 22.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 136 | 166 | $4,814 | $1,280 | 26.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 21 | 22 | $3,542 | $1,071 | 30.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 137 | 173 | $1,557 | $515.16 | 33.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 14 | 15 | $2,010 | $506.51 | 25.2% |
About Michelle Wright Mast, NP
Michelle Wright Mast, NP is a Family healthcare provider based in Carmel, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/28/2007. The National Provider Identifier (NPI) number assigned to this provider is 1538353073.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michelle Wright Mast, NP has received a total of $6,091 in payments from pharmaceutical and medical device companies, with $3,073 received in 2024. These payments were reported across 212 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($4,095).
As a Medicare-enrolled provider, Wright Mast has provided services to 1,317 Medicare beneficiaries, totaling 1,821 services with total Medicare billing of $99,161. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Other Specialties Nurse Practitioner, Family
- Location Carmel, IN
- Active Since 08/28/2007
- Last Updated 03/26/2025
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1538353073
Products in Payments
- KISQALI (Drug) $1,427
- IMBRUVICA (Drug) $213.86
- TUKYSA (Drug) $161.20
- JEVTANA (Drug) $154.28
- JAKAFI (Drug) $147.78
- SARCLISA (Biological) $135.89
- EPKINLY (Drug) $131.81
- DOPTELET (Drug) $123.63
- Orserdu (Drug) $121.18
- PROMACTA (Drug) $106.03
- Tavalisse (Drug) $94.31
- INJECTAFER (Drug) $93.48
- LUMAKRAS (Drug) $89.61
- MONOFERRIC (Drug) $82.89
- PIQRAY (Drug) $81.53
- REBLOZYL (Biological) $80.43
- Lenvima (Drug) $75.96
- Xtandi (Drug) $75.45
- BELEODAQ (Drug) $75.27
- OPDIVO (Biological) $72.84
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Carmel
Mrs. Rebecca O'bryan, Aprn Fnp-C, APRN FNP-C
Family — Payments: $6,183
Family $6,183
Mrs. Smitha John, Fnp, FNP
Family — Payments: $5,460
Family $5,460
Dr. Renee Mcdougal
Family — Payments: $5,221
Family $5,221
Aleena Ashok Malayil, Fnp, FNP
Family — Payments: $5,208
Family $5,208
Rachel Lytle, Np, NP
Family — Payments: $5,144
Family $5,144
Christine Thumma, Np, NP
Family — Payments: $3,639
Family $3,639